Bone and soft tissue sarcomas are often curable-But at what cost?
نویسندگان
چکیده
منابع مشابه
Pediatric bone and soft-tissue sarcomas
In this session I will review the clinical and imaging features of the most common pediatric bone and soft tissue sarcomas and several benign lesions that may mimic them. These malignancies often have unique features that can help narrow the differential diagnosis. The material will be presented in an informal manner and audience participation is encouraged. A review of the appropriate diagnost...
متن کامل[Treatment of bone and soft tissue sarcomas].
Why should wait for some days to get or receive the treatment of bone and soft tissue sarcomas book that you order? Why should you take it if you can get the faster one? You can find the same book that you order right here. This is it the book that you can receive directly after purchasing. This treatment of bone and soft tissue sarcomas is well known book in the world, of course many people wi...
متن کاملEpidemiology of bone and soft tissue sarcomas.
Although bone and soft tissue sarcomas are not common, a significant number of patients who develop these tumors will die with metastatic disease. Part of the reason is that many of the patients have advanced disease at diagnosis. Identification of an etiologic agent should allow for diagnosis at an earlier stage. This is particularly true of radiation-induced sarcomas because patients who deve...
متن کاملImmunotherapy for Bone and Soft Tissue Sarcomas
Although multimodal therapies including surgery, chemotherapy, and radiotherapy have improved clinical outcomes of patients with bone and soft tissue sarcomas, the prognosis of patients has plateaued over these 20 years. Immunotherapies have shown the effectiveness for several types of advanced tumors. Immunotherapies, such as cytokine therapies, vaccinations, and adoptive cell transfers, have ...
متن کاملCurrent Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas
Systemic treatment options for bone and soft tissue sarcomas remained unchanged until the 2000s. These cancers presented challenges in new drug development partly because of their rarity and heterogeneity. Many new molecular targeting drugs have been tried in the 2010s, and some were approved for bone and soft tissue sarcoma. As one of the first molecular targeted drugs approved for solid malig...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 2009
ISSN: 0008-543X,1097-0142
DOI: 10.1002/cncr.24458